Literature DB >> 19521335

Good laboratory practices for molecular genetic testing for heritable diseases and conditions.

Bin Chen1, MariBeth Gagnon, Shahram Shahangian, Nancy L Anderson, Devery A Howerton, Joe D Boone.   

Abstract

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) regulations, laboratory testing is categorized as waived (from routine regulatory oversight) or nonwaived based on the complexity of the tests; tests of moderate and high complexity are nonwaived tests. Laboratories that perform molecular genetic testing are subject to the general CLIA quality systems requirements for nonwaived testing and the CLIA personnel requirements for tests of high complexity. Although many laboratories that perform molecular genetic testing comply with applicable regulatory requirements and adhere to professional practice guidelines,specific guidelines for quality assurance are needed to ensure the quality of test performance. To enhance the oversight of genetic testing under the CLIA framework,CDC and the Centers for Medicare & Medicaid Services (CMS) have taken practical steps to address the quality management concerns in molecular genetic testing,including working with the Clinical Laboratory Improvement Advisory Committee (CLIAC). This report provides CLIAC recommendations for good laboratory practices for ensuring the quality of molecular genetic testing for heritable diseases and conditions. The recommended practices address the total testing process (including the preanalytic,analytic,and postanalytic phases),laboratory responsibilities regarding authorized persons,confidentiality of patient information,personnel competency,considerations before introducing molecular genetic testing or offering new molecular genetic tests,and the quality management system approach to molecular genetic testing. These recommendations are intended for laboratories that perform molecular genetic testing for heritable diseases and conditions and for medical and public health professionals who evaluate laboratory practices and policies to improve the quality of molecular genetic laboratory services. This report also is intended to be a resource for users of laboratory services to aid in their use of molecular genetic tests and test results in health assessment and care. Improvements in the quality and use of genetic laboratory services should improve the quality of health care and health outcomes for patients and families of patients.

Entities:  

Mesh:

Year:  2009        PMID: 19521335

Source DB:  PubMed          Journal:  MMWR Recomm Rep        ISSN: 1057-5987


  37 in total

1.  Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project.

Authors:  Victoria M Pratt; Barbara Zehnbauer; Jean Amos Wilson; Ruth Baak; Nikolina Babic; Maria Bettinotti; Arlene Buller; Ken Butz; Matthew Campbell; Chris Civalier; Abdalla El-Badry; Daniel H Farkas; Elaine Lyon; Saptarshi Mandal; Jason McKinney; Kasinathan Muralidharan; LeAnne Noll; Tara Sander; Junaid Shabbeer; Chingying Smith; Milhan Telatar; Lorraine Toji; Anand Vairavan; Carlos Vance; Karen E Weck; Alan H B Wu; Kiang-Teck J Yeo; Markus Zeller; Lisa Kalman
Journal:  J Mol Diagn       Date:  2010-10-01       Impact factor: 5.568

2.  Characterization of 108 Genomic DNA Reference Materials for 11 Human Leukocyte Antigen Loci: A GeT-RM Collaborative Project.

Authors:  Maria P Bettinotti; Deborah Ferriola; Jamie L Duke; Timothy L Mosbruger; Nikolaos Tairis; Lawrence Jennings; Lisa V Kalman; Dimitri Monos
Journal:  J Mol Diagn       Date:  2018-06-26       Impact factor: 5.568

3.  Clinical Pharmacogenomics: Applications in Nephrology.

Authors:  Solomon M Adams; Karryn R Crisamore; Philip E Empey
Journal:  Clin J Am Soc Nephrol       Date:  2018-05-23       Impact factor: 8.237

Review 4.  Reference standards for next-generation sequencing.

Authors:  Simon A Hardwick; Ira W Deveson; Tim R Mercer
Journal:  Nat Rev Genet       Date:  2017-06-19       Impact factor: 53.242

Review 5.  Current landscape and new paradigms of proficiency testing and external quality assessment for molecular genetics.

Authors:  Lisa V Kalman; Ira M Lubin; Shannon Barker; Desiree du Sart; Rob Elles; Wayne W Grody; Mario Pazzagli; Sue Richards; Iris Schrijver; Barbara Zehnbauer
Journal:  Arch Pathol Lab Med       Date:  2013-07       Impact factor: 5.534

Review 6.  Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting.

Authors:  L V Kalman; Jag Agúndez; M Lindqvist Appell; J L Black; G C Bell; S Boukouvala; C Bruckner; E Bruford; K Caudle; S A Coulthard; A K Daly; Al Del Tredici; J T den Dunnen; K Drozda; R E Everts; D Flockhart; R R Freimuth; A Gaedigk; H Hachad; T Hartshorne; M Ingelman-Sundberg; T E Klein; V M Lauschke; D R Maglott; H L McLeod; G A McMillin; U A Meyer; D J Müller; D A Nickerson; W S Oetting; M Pacanowski; V M Pratt; M V Relling; A Roberts; W S Rubinstein; K Sangkuhl; M Schwab; S A Scott; S C Sim; R K Thirumaran; L H Toji; R F Tyndale; Rhn van Schaik; M Whirl-Carrillo; Ktj Yeo; U M Zanger
Journal:  Clin Pharmacol Ther       Date:  2015-11-20       Impact factor: 6.875

7.  Development of a genomic DNA reference material panel for Rett syndrome (MECP2-related disorders) genetic testing.

Authors:  Lisa V Kalman; Jack C Tarleton; Alan K Percy; Swaroop Aradhya; Sherri Bale; Shannon D Barker; Pinar Bayrak-Toydemir; Christina Bridges; Arlene M Buller-Burckle; Soma Das; Ramaswamy K Iyer; Timothy D Vo; Val V Zvereff; Lorraine H Toji
Journal:  J Mol Diagn       Date:  2014-02-07       Impact factor: 5.568

8.  Health Care Infrastructure for Financially Sustainable Clinical Genomics.

Authors:  Jochen K Lennerz; Heather M McLaughlin; Jason M Baron; David Rasmussen; Meini Sumbada Shin; Nancy Berners-Lee; Julie Miller Batten; Kathryn J Swoboda; Manish K Gala; Harland S Winter; Jeremy D Schmahmann; David A Sweetser; Marianne Boswell; Maciej Pacula; Albrecht Stenzinger; Long P Le; William Hynes; Heidi L Rehm; Anne Klibanski; Stephen W Black-Schaffer; Jeffrey A Golden; David N Louis; Scott T Weiss; A John Iafrate
Journal:  J Mol Diagn       Date:  2016-07-25       Impact factor: 5.568

9.  Refining the structure and content of clinical genomic reports.

Authors:  Michael O Dorschner; Laura M Amendola; Brian H Shirts; Lesli Kiedrowski; Joseph Salama; Adam S Gordon; Stephanie M Fullerton; Peter Tarczy-Hornoch; Peter H Byers; Gail P Jarvik
Journal:  Am J Med Genet C Semin Med Genet       Date:  2014-03-10       Impact factor: 3.908

10.  The clinical utility of molecular diagnostic testing for primary immune deficiency disorders: a case based review.

Authors:  Rohan Ameratunga; See-Tarn Woon; Katherine Neas; Donald R Love
Journal:  Allergy Asthma Clin Immunol       Date:  2010-06-08       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.